A new standard of care for advanced lung cancer: whats next for pembrolizumab?

The anti-PD-1 antibody therapy pembrolizumab is an exciting new agent for the treatment of non-small cell lung cancer (NSCLC). Here, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdo... Author: VJOncology Added: 04/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts